Adrestia Therapeutics

We are leaders in synthetic rescue, an approach that decodes the complexity of genetic networks to reveal new ways to treat diseases. Decades of research from the laboratory of synthetic lethality pioneer Professor Steve Jackson inform our platform which is already delivering world-first, validated targets and a pipeline that offers new hope for people suffering with devastating genetic diseases. We have established a multi-target discovery alliance with GSK, which co-funded our Series A along with Ahren Innovation Capital.